This paper reviews common advertising claims by egg freezing companies and evaluates the medical evidence behind those claims. It then surveys legal standards for truth in advertising, including FTC and FDA regulations and the First Amendment right to free speech. Professional standards for medical advertising, such as guidelines published by the American Society for Reproductive Medicine (ASRM), the American College of Obstetricians and Gynecologists (ACOG), and the American Medical Association (AMA), are also summarized. A number of claims, many of which relate to the targeting of younger women for eOC, are found to breach legal and ethical standards for truth in advertising. The ethical implications of misleading advertising claims are also discussed, and the central narrative woven by OC ads — that egg freezing is empowering to women — is examined. The paper concludes that a more balanced approach to the risks and benefits of OC is necessary to truly respect women's autonomy. Moreover, justice requires us to look beyond a medical procedure accessible only to a minority of women in order to address inequities in the workplace.
Get full access to this article
View all access options for this article.
References
1.
Personal communication from Ethan Wantman, American Society for Reproductive Medicine, to author (MJB) (May 1, 2019).
V.Vloeberghs, K.Peeraer, A.Pexsters, et al., “Ovarian Hyper-stimulation Syndrome and Complications of ART,”Best Practice & Research Clinical Obstetrics and Gynaecology23, no. 5 (2009): 691-709.
5.
S.Avraham, R.Machtinger, T.Cahan, A.Sokolov, C.Racowsky, and D.S.Seidman, “What is the Quality of Information on Social Oocyte Cryopreservation Provided by Websites of Society for Assisted Reproductive Technology Member Fertility Clinics?”Fertility and Sterility101, no. 1 (2014): 222-226.
6.
C.Barbey, “Evidence of Biased Advertising in the Case of Social Egg Freezing,”The New Bioethics23, no. 3 (2017): 195-209.
7.
M.A.Winker, A.Flanagin, B.Chi-Lum, et al., “Guidelines for Medical and Health Information Sites on the Internet: Principles Governing AMA Web Sites,”Journal of the American Medical Association283, no. 12 (2000): 1600-1606.
8.
M.E.Abusief, M. D.Hornstein, and T.Jain, “Assessment of United States Fertility Clinic Websites According to the American Society for Reproductive Medicine/Society for Assisted Reproductive Technology Guidelines,”Fertility and Sterility87, no. 1 (2007): 88-92.
9.
J.Hawkins, “Selling ART: An Empirical Assessment of Advertising on Fertility Clinics’ Websites,”Indiana Law Journal88, no. 4 (2013): 1147-1179.
10.
L.Campo-Engelstein, R.Aziz, S.Darivemula, et al., “Freezing Fertility or Freezing False Hope? A Content Analysis of Social Egg Freezing in U.S. Print Media,”American Journal of Bio-ethics Empirical Bioethics9, no. 3 (2018): 181-193.
11.
H.F.Hsieh and Shannon, S.E.“Three Approaches to Qualitative Content Analysis,”Qualitative Health Research15, no. 9 (2005): 1277–1288.
E.Reis and S.Reis-Dennis, “Freezing Eggs and Creating Patients: Moral Risks of Commercialized Fertility,”Hastings Center Report47 (2017): S41-S45.
18.
Several months after data collection, it was noted that four companies introduced statistics to their websites. Two refer only to the rates of pregnancy, rather than live birth. Two others provide reasonably accurate representations of the chance of one live birth.
B.Hodes-Wertz, S.Druckenmiller, M.Smith, et al., “What do Reproductive-Age Women who undergo Oocyte Cryopreservation Think about the Process as a Means to Preserve Fertility?”Fertility and Sterility100, no. 5 (2013): 1343-1349.
21.
A.Cobo, J.A.Garcia-Velasco, J.Domingo, et al., “Oocyte Vitrification as an Efficient Option for Elective Fertility Preservation,”Fertility and Sterility105, no. 3 (2016): 755-764.
22.
E.A.Greenwood, L.A.Pasch, J.Hastie, et al., “To Freeze or Not to Freeze: Decision Regret and Satisfaction Following Elective Oocyte Cryopreservation,”Fertility and Sterility109, no. 6 (2018): 1097-1104.
23.
T.B.Mesen, J.E.Mersereau, J.B.Kane, et al., “Optimal Timing for Elective Egg Freezing,”Fertility and Sterility103, no. 6 (2015): 1551-1556.
24.
J.Hirshfeld-Cytron, W.A.Grobman, and M.P.Milad, “Fertility Preservation for Social Indications: A Cost-Based Decision Analysis,”Fertility and Sterility97, no. 3 (2012): 665-670.
The Practice Committees of the American Society for Reproductive Medicine and the Society for Assisted Reproductive Technology, “Mature Oocyte Cryopreservation: A Guideline,”Fertility and Sterility99, no. 1 (2013): 37-43.
27.
Y.J.Lee, M.N.Kim, Y.M.Kim, et al., “Perinatal Outcome of Twin Pregnancies According to Maternal Age,”Obstetrics and Gynecology Science62, no. 2 (2019): 93-102.
S.Y.Kim, J.Y.Park, S.E.Bak, et al., “Effect of Maternal Age on Emergency Cesarean Section,”Journal of Maternal-Fetal and Neonatal Medicine, E-pub (2019), DOI: 10.1080/14767058.2019.1593958.
30.
S.Lisonkova, J.Potts, and G.M.Muraca, “Maternal Age and Severe Maternal Morbidity: A Population-Based Retrospective Cohort Study,”PLoS Medicine14, no. 5 (2017): e1002307.
31.
D.F.Meyer, “Psychosocial Needs of First-Time Mothers over 40,”Journal of Women and Aging, E-pub (2019), DOI: 10.1080/08952841.2019.1593798.
32.
G.Sydsjo, M.L.Pettersson, A.S.Svanberg, et al., “Evaluation of Risk Factors’ Importance on Adverse Pregnancy and Neonatal Outcomes in Women Aged 40 Years or Older,”BMC Pregnancy and Childbirth19, no. 1 (2019): 92-102.
33.
S.Cnattingius, M.R.Forman, H.W.Berendes, et al, “Delayed Childbearing and Risk of Adverse Perinatal Outcome. A Population-Based Study,”Journal of the American Medical Association268, no. 7 (1992): 886-890.
34.
H.C.Glass, A.T.Costarino, S.A.Stayer, et al., “Outcomes for Extremely Premature Infants,”Anesthesia and Analgesia120, no. 6 (2015): 1337-1351.
35.
K.E.Gregory, C.E.DeForge, K.M.Natale, et al., “Necrotizing Enterocolitis in the Premature Infant,”Advances in Neonatal Care11, no. 3 (2011): 155-166.
36.
P.Ballabh, “Intraventricular Hemorrhage in Premature Infants: Mechanism of Disease,”Pediatric Research67, no. 1 (2010): 1-8.
37.
R.W.Rebar, “Social and Ethical Implications of Fertility Preservation,”Fertility and Sterility105, no. 6 (2016): 1449-1451.
38.
See The Practice Committees of the American Society for Reproductive Medicine and the Society for Assisted Reproductive Technology, supra note 26.
39.
See Greenwood et al., supra note 22.
40.
M.E.Lemoine and V.Ravitsky, “Sleepwalking into Infertility: The Need for a Public Health Approach toward Advanced Maternal Age,”American Journal of Bioethics15, no. 11 (2015): 37-48.
41.
R.H.Goldman, C.Racowsky, L.V.Farland, et al., “Predicting the Likelihood of Live Birth for Elective Oocyte Cryopreservation: A Counseling Tool for Physicians and Patients,”Human Reproduction32, no. 4 (2017): 853-859.
42.
Id., supplementary materials; European Society of Human Reproduction and Embryology, “Freeze-Storage Egg Banking for Egg Donation Treatment,”ScienceDaily, July1, 2014, available at <https://www.sciencedaily.com/releases/2014/07/140701091450.htm> (last visited Nov. 12, 2019).
43.
See Goldman et al., supra note 42.
44.
Id.
45.
J.O.Doyle, K.S.Richter, J.Lim, et al., “Successful Elective and Medically Indicated Oocyte Vitrification and Warming for Autologous in Vitro Fertilization, with Predicted Birth Probabilities for Fertility Preservation According to Number of Cryopreserved Oocytes and Age at Retrieval,”Fertility and Sterility105, no. 2 (2016): 459-466.
46.
See Goldman et al., supra note 41, at supplementary materials.
47.
S.M.Zarek, E.M.Mitchell, and L.A.Sjaarda, “Is Anti-Müllerian Hormone Associated With Fecundability? Findings from the EAGeR Trial,”Journal of Clinical Endocrinology and Metabolism100, no. 11 (2015): 4215-4221.
48.
M.Depmann, S.L.Broer, and M.J.C.Eijkemans, “Anti-Müllerian Hormone Does Not Predict Time to Pregnancy: Results of a Prospective Cohort Study,”Gynecological Endocrinology33, no. 8 (2017): 644-648.
49.
L.M.Schwartz and S.Woloshin, “Medical Marketing in the United States, 1997-2016,”Journal of the American Medical Association321, no. 1 (2019): 80-96.
50.
Id.
51.
Federal Trade Commission Act, 15 U.S.C. §55 (1914).
L.Noah, “Truth or Consequences?: Commercial Free Speech vs. Public Health Promotion (at the FDA),”Health Matrix: The Journal of Law-Medicine21, no. 5 (2011): 31-95.
62.
EU Directive 92/28/EC.
63.
Y.Schenker, R. M.Arnold, and A.J.London, “The Ethics of Advertising for Health Care Services,”American Journal of Bioethics14, no. 3 (2014): 34-43.
64.
21 CFR 202.1(e)(5).
65.
B.P.Keller, “It Keeps Going and Going and Going: The Expansion of False Advertising Litigation under the Lanham Act,”Law and Contemporary Problems59, no. 2 (1996): 131-157.
66.
Lanham Act 15 U.S.C. § 1125(a) (Section 43b).
67.
G.P.Meyer, “Standing Out: A Commonsense Approach to Standing for False Advertising Suits Under Lanham Act Section 43(a),”University of Illinois Law Review1 (2009): 295-350.
68.
See Keller, supra note 66.
69.
Id.
70.
2013 New York Consolidated Laws, General Business Article 22A (349-350-F-1).
71.
New York State Attorney General Letitia James, “Bureau of Consumer Frauds and Protection,”Economic Justice, available at <https://ag.ny.gov/bureau/consumer-frauds-bureau> (last visited Nov. 12, 2019).
72.
See Schwartz and Woloshin, supra note 50.
73.
Id.
74.
See The Practice Committees of the American Society for Reproductive Medicine and the Society for Assisted Reproductive Technology, supra note 26.
75.
Ethics Committee of the American Society for Reproductive Medicine, “Planned Oocyte Cryopreservation for Women Seeking to Preserve Future Reproductive Potential: An Ethics Committee Opinion,”Fertility and Sterility110, no. 6 (2018): 1022-1028.
S.R.Latham, “Ethics in the Marketing of Medical Services,”Mount Sinai Journal of Medicine71, no. 4 (2004): 243-50.
94.
See Schenker et al., supra note 64.
95.
See Latham, supra note 94.
96.
See Hodes-Wertz, supra note 20; G.M.Lockwood, “Social Egg Freezing: The Prospect of Reproductive ‘Immortality’ or a Dangerous Delusion?”Reproductive Biomedicine Online23, no. 3 (2011): 334-340.
97.
See Hodes-Wertz, supra note 20.
98.
I.Goold, “Trust Women to Choose: A Response to John a Robertson’s ‘Egg Freezing and Egg Banking: Empowerment and Alienation in Assisted Reproduction,”Journal of Law and Biosciences4, no. 3 (2017): 507-541.
F.Baylis, “Left out in the Cold: Arguments against Non-Medical Oocyte Cryopreservation,”Journal of Obstetrics and Gynaecology Canada37, no. 1 (2015): 64-67.
103.
B.Schwartz and A.Ward, “Doing Better but Feeling Worse: The Paradox of Choice,” in Positive Psychology in Practice, P.A.Linley and S.Joseph, eds., (John Wiley & Sons, Inc., 2004): 86-104.
104.
S.Shkedi-Rafud and Y.Hashiloni-Dolev, “Egg Freezing for Non-Medical Uses: The Lack of a Relational Approach to Autonomy in the New Israeli Policy and in Academic Discussion,”Journal of Medical Ethics38, no. 3 (2012): 154-157.
105.
See Reis and Reis-Dennis, supra note 17; See Mohapatra, supra note 55; K.Harwood, “Egg Freezing: A Breakthrough for Reproductive Autonomy?”Bioethics23, no. 1 (2009): 39-46.
106.
See Harwood, supra note 106.
107.
See Mohapatra, supra note 55.
108.
See Lemoine and Ravitsky, supra note 41; J.A.Robertson, “Egg Freezing and Egg Banking: Empowerment and Alienation in Assisted Reproduction,”Journal of Law and Biosciences1, no. 2 (2014): 113-136.
109.
See Baylis, supra note 103.
110.
See Shkedi-Rafud and Hashiloni-Dolev, supra note 105; A.C.McGinley, “Subsidized Egg Freezing in Employment: Autonomy, Coercion, or Discrimination?”Employee Rights and Employment Policy Journal20 (2016): 331-364.
111.
L.Gordon, “Voluntary Motherhood: The Beginnings of Feminist Birth Control Ideas in the United States,”Feminist Studies1, no. 3 (1973): 5-22.
112.
I.Goold, J.Savulescu, “In Favour of Freezing Eggs for Non-Medical Reasons,”Bioethics23, no. 1 (2009): 47-58.
